EPCAM and carcinoma: Moreover, because EpCAM-based technologies for CTC detection are optimized for carcinoma, they are not appropriate for detecting CTCs derived from mesenchymal cancers (sarcoma, lymphoma, and neurogenic tumors) [19,31].